Nrx pharmaceuticals announces further alignment with fda on initiation of registrational trials for nrx-101 in the treatment of chronic pain

"study may proceed" letter received from fda ind preclinical requirements are consistent with studies already in progress to support treatment of bipolar depression potential to initiate registrational studies in 2024, pending receipt of data from already-completed dod-funded trial of d-cycloserine radnor, pa. , oct. 26, 2023 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company today announced further alignment with the fda division of anesthesiology, addiction medicine, and pain medicine in connection with the development of nrx-101 for treatment of chronic pain.
NRXP Ratings Summary
NRXP Quant Ranking